MADRIGAL PHARMACEUTICALS, INC. Net Income (Loss) Attributable to Parent in USD from 2016 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Madrigal Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2016 to Q3 2025.
  • Madrigal Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2025 was -$114M, a 6.76% decline year-over-year.
  • Madrigal Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2025 was -$289M, a 44.3% increase year-over-year.
  • Madrigal Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$466M, a 24.7% decline from 2023.
  • Madrigal Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$374M, a 26.5% decline from 2022.
  • Madrigal Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$295M, a 22.1% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)

MADRIGAL PHARMACEUTICALS, INC. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$289M -$114M -$7.23M -6.76% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-04
Q2 2025 -$282M -$42.3M +$110M +72.2% Apr 1, 2025 Jun 30, 2025 10-Q 2025-11-04
Q1 2025 -$392M -$73.2M +$74.3M +50.4% Jan 1, 2025 Mar 31, 2025 10-Q 2025-11-04
Q4 2024 -$466M -$59.4M +$52.8M +47% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-26
Q3 2024 -$519M -$107M -$8.22M -8.33% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-04
Q2 2024 -$510M -$152M -$66.2M -77.1% Apr 1, 2024 Jun 30, 2024 10-Q 2025-11-04
Q1 2024 -$444M -$148M -$70.6M -91.9% Jan 1, 2024 Mar 31, 2024 10-Q 2025-11-04
Q4 2023 -$374M -$112M -$26.3M -30.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 -$347M -$98.7M -$17.5M -21.6% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 -$330M -$85.8M -$15.1M -21.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-10-31
Q1 2023 -$315M -$76.9M -$19.4M -33.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-10-31
Q4 2022 -$295M -$85.9M -$21.4M -33.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 -$274M -$81.2M -$18.1M -28.7% Jul 1, 2022 Sep 30, 2022 10-K 2024-02-28
Q2 2022 -$256M -$70.7M -$9.08M -14.7% Apr 1, 2022 Jun 30, 2022 10-K 2024-02-28
Q1 2022 -$247M -$57.5M -$4.97M -9.46% Jan 1, 2022 Mar 31, 2022 10-K 2024-02-28
Q4 2021 -$242M -$64.5M -$5.43M -9.18% Oct 1, 2021 Dec 31, 2021 10-K/A 2023-03-03
Q3 2021 -$236M -$63.1M -$5.14M -8.86% Jul 1, 2021 Sep 30, 2021 10-K/A 2023-03-03
Q2 2021 -$231M -$61.7M -$12.6M -25.8% Apr 1, 2021 Jun 30, 2021 10-K/A 2023-03-03
Q1 2021 -$219M -$52.5M -$16.4M -45.4% Jan 1, 2021 Mar 31, 2021 10-K/A 2023-03-03
Q4 2020 -$202M -$59.1M -$31.4M -113% Oct 1, 2020 Dec 31, 2020 10-K 2022-02-24
Q3 2020 -$171M -$58M -$36.5M -170% Jul 1, 2020 Sep 30, 2020 10-K 2022-02-24
Q2 2020 -$134M -$49M -$29.3M -149% Apr 1, 2020 Jun 30, 2020 10-K 2022-02-24
Q1 2020 -$105M -$36.1M -$21.1M -140% Jan 1, 2020 Mar 31, 2020 10-K 2022-02-24
Q4 2019 -$83.9M -$27.7M -$16.3M -142% Oct 2, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 -$67.7M -$21.4M -$12.9M -152% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-25
Q2 2019 -$54.8M -$19.7M -$13.2M -205% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-25
Q1 2019 -$41.5M -$15.1M -$8.72M -137% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-25
Q4 2018 -$32.8M -$11.5M -$3.03M -35.9% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-26
Q3 2018 -$29.8M -$8.51M -$149K -1.78% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-26
Q2 2018 -$29.6M -$6.46M +$1.89M +22.6% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-26
Q1 2018 -$31.5M -$6.36M -$365K -6.08% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-26
Q4 2017 -$31.2M -$8.45M Oct 1, 2017 Dec 31, 2017 10-K 2019-02-27
Q3 2017 -$8.36M Jul 1, 2017 Sep 30, 2017 10-K 2019-02-27
Q2 2017 -$8.35M Apr 1, 2017 Jun 30, 2017 10-K 2019-02-27
Q1 2017 -$6M Jan 1, 2017 Mar 31, 2017 10-K 2019-02-27

MADRIGAL PHARMACEUTICALS, INC. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$466M -$92.3M -24.7% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-26
2023 -$374M -$78.3M -26.5% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-26
2022 -$295M -$53.5M -22.1% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-26
2021 -$242M -$39.6M -19.6% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 -$202M -$118M -141% Jan 1, 2020 Dec 31, 2020 10-K/A 2023-03-03
2019 -$83.9M -$51.1M -156% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-24
2018 -$32.8M -$1.66M -5.32% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
2017 -$31.2M -$4.77M -18.1% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-26
2016 -$26.4M Jan 1, 2016 Dec 31, 2016 10-K 2019-02-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.